other
confidence high
sentiment positive
materiality 0.55
Grace Therapeutics receives sixth U.S. patent for GTx-104 dosing regimen; protection extended to 2043
Grace Therapeutics, Inc.
- US Patent 12,414,943 issued for I.V. nimodipine dosing regimen used in Phase 3 STRIVE-ON trial.
- First method-of-use patent for GTx-104; adds to five composition patents expiring 2037.
- Patent protection for GTx-104 extended to 2043.
- GTx-104 is a clinical-stage injectable nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).
- Orphan Drug Designation provides 7 years of marketing exclusivity upon FDA approval.